Site Feasibility & Selection
We assess protocols, target patient populations, and site-specific capabilities to select the countries and sites best suited to a successful clinical trial.
Evidence-Based Site Selection
Close collaboration with leading clinical trials centers in Korea.
Trial sites should be selected on the basis of evidence. Patient data, indication-specific expertise, and direct collaboration with hospitals support these decisions.
ACRO develops feasibility strategies using actual data and works with sponsors throughout the process.
Why it matters
Feasibility is the starting point for subsequent decisions on sample size, recruitment timelines, the sequence of regulatory activities, and budgets. When initial assumptions do not match reality, later decisions are also affected. In oncology, where competition is intense and eligible patient populations are small, poor feasibility assumptions create increasing burdens at every stage.
What we offer
- Real-world data-based country and site feasibility analysis
- Estimation of eligible patient populations by indication
- Assessment of competing clinical trials
- Investigator and site identification through hospital networks
- Scenario-based enrollment forecasting
- Site qualification consulting
How we work
Our medical and biostatistical specialists work as one team. We estimate eligible patient populations using real-world data, assess competing trials, and validate assumptions directly with hospital partners. The result is a site selection strategy sponsors can confidently support.
Related services
- Biostatistics — Feasibility findings inform sample size and stratification design.
- Protocol Development — Eligibility criteria are refined using feasibility findings.
- IND Strategy — Country selection informs the sequence of regulatory activities.